Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 16/20 | 1.00 |
| ▸ | HTR2B | P41595 | 13/20 | 1.00 |
| ▸ | HTR2A | P28223 | 9/20 | 0.66 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.66 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.66 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.66 |
| ▸ | MAOB | P27338 | 4/20 | 0.64 |
| ▸ | KDM1A | O60341 | 4/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.57 |
| ▸ | RCOR1 | Q9UKL0 | 2/20 | 0.57 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13742101 | 1.00 | HTR2C (1.00) | HTR2CHTR2BHTR2ASLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL4133961 | 0.98 | HTR2C (1.00) | HTR2CHTR2BHTR2ASLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL4133959 | 0.98 | HTR2C (1.00) | HTR2CHTR2BHTR2ASLC6A2SLC6A4 | |
| SCHEMBL14697357 | 0.79 | HTR2C (1.00) | HTR2CHTR2BHTR2ASLC6A2SLC6A4 | |
| SCHEMBL14708135 | 0.79 | HTR2C (1.00) | HTR2CHTR2BHTR2ASLC6A2SLC6A4 | |
| SCHEMBL4893904 | 0.79 | HTR2C (0.66) | HTR2CHTR2BHTR2ASLC6A2SLC6A4 | |
| SCHEMBL22334928 | 0.79 | HTR2C (0.66) | HTR2CHTR2BHTR2ASLC6A2SLC6A4 | |
| SCHEMBL20570045 | 0.79 | HTR2C (0.66) | HTR2CHTR2BHTR2ASLC6A2SLC6A4 | |
| SCHEMBL20570046 | 0.79 | HTR2C (0.66) | HTR2CHTR2BHTR2ASLC6A2SLC6A4 | |
| SCHEMBL13742128 | 0.79 | HTR2C (1.00) | HTR2CHTR2BHTR2ASLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8853390-B2 | Processes for preparing 1,2-substituted cyclopropyl derivatives | ABBVIE INC. (US) | 2014-10-07 | — | — | US | disclosed |
| US-20120071651-A1 | Processes for Preparing 1,2-Substituted Cyclopropyl Derivatives | ABBOTT LABORATORIES (US) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071651-A1 | Processes for Preparing 1,2-Substituted Cyclopropyl Derivatives | HRH3, HRH4, HRH1 | HTR2C 174/4885HTR2B 210/4885HTR2A 165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.